Axonics, Medtronic
Axonics defeats Medtronic lawsuit in spine-stimulation patent trial
Medical device maker Axonics has convinced a jury in California federal court that it did not violate rival Medtronic's patent rights in nerve-stimulation technology.
Axonics did not infringe Medtronic’s patents, jury rules
The Court for the Central District of California has sided with Axonics finding the company did not breach Medtronic’s patents with its r-SNM devices.
Jury rules for Axonics in Medtronic’s long-running neuromodulation patent lawsuit
A federal jury in California has found that Axonics’ neurostimulators and electric leads for treating incontinence do not run afoul of three patents held by the company’s main rival, Medt | The case is one of several intellectual property disputes between the medtech giant and Axonics—which is currently waiting to become a subsidiary of Boston Scientific.
Jury says Axonics didn’t infringe on Medtronic patents
Axonics (Nasdaq:AXNX) announced today that a jury unanimously ruled in its favor in a patent spat with (NYSE: MDT).
Jury sides with Axonics in Medtronic patent dispute
Meanwhile, Boston Scientific is still waiting for antitrust regulators to conclude their review of its proposal to buy Axonics, which was announced in January.
Axonics gains after win in trial in patent dispute with Medtronic
Axonics Inc. (NASDAQ:AXNX) rose 1.5% in after hours trading after a jury voted in is favor in a patent dispute with Medtronic (MDT). Medtronic (MDT) was seeking $150 million in a patent dispute with Axonics (AXNX),
Medtronic’s Aurora EV-ICD to challenge Boston Scientific’s S-ICD market leadership
"Medtronic’s Aurora EV-ICD to challenge Boston Scientific’s S-ICD market leadership" was originally created and published by ...
MassDevice1d
Medtronic has a new VP, GM for TAVR, Congenital Heart
Medtronic (NYSE: MDT) has named Jorie Soskin as its new VP and GM of its TAVR and Congenital Heart businesses.
Medtronic Buy Rating Affirmed: Sustained Growth and Strong Pipeline Drive Positive Outlook
Analyst Travis Steed of Bank of America Securities maintained a Buy rating on Medtronic (MDT – Research Report), retaining the price ...
Medtronic: An Undervalued Stock With Durable Competitive Advantages
Medtronic, a global developer and manufacturer of medical devices for chronic diseases, is now a $111 billion (by market cap) ...
health.economictimes.indiatimes2d
FDA recall orders for McGrath Mac’s Medtronic laryngoscope may hurt device sales: GlobalData
According to GlobalData, the decision of the US regulator is likely to hurt Medtronic's sales, which currently occupies ...
MarketBeat on MSN12d
Medtronic Stock: Growth On Rise of the Cardiovascular Machines
Medtronic plc (NYSE: MDT) is a leading global medical device maker in the medical sector. Its innovative and critical medical ...
3 Reasons Medtronic's Stock Can Continue Rallying Higher
Medtronic may be an underrated beneficiary of declining interest rates. That's because as rates come down, it becomes less ...